Viewing data from:

BENSULFOID

NDA

SULFUR | N002918 | WILLIAM P POYTHRESS AND CO INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

112 trials from ClinicalTrials.gov — 60 recruiting, 29 active, 18 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases NCT03175432	Phase 2	Active	M.D. Anderson Cancer Center	29	2017-06-15 → 2028-06-30
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02839707	Phase 2/3	Active	National Cancer Institute (NCI)	444	2017-06-23 → 2027-05-11
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants NCT07534592	Phase 1	Active	AstraZeneca	48	2026-04-16 → 2026-08-28
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma NCT06169215	Phase 2	Active	National Cancer Institute (NCI)	70	2024-07-23 → 2026-09-30
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)NCT07216482	Phase 3	Active	Merck Sharp & Dohme LLC	975	2025-11-11 → 2027-03-01
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients NCT03127631	N/A	Active	McMaster University	5,000	2015-10-21 → 2026-12-31
DARA RVD For High Risk SMM NCT04775550	Phase 2	Active	Omar Nadeem, MD	61	2021-03-08 → 2030-12-08
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC NCT04227028	Phase 1	Active	City of Hope Medical Center	5	2020-03-09 → 2027-03-25
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT01562405	Phase 1	Active	Massachusetts General Hospital	33	2012-05 → 2027-12
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation NCT04098393	Phase 1	Active	Memorial Sloan Kettering Cancer Center	39	2019-09-18 → 2026-09

Source: ClinicalTrials.gov. Trials matched by ingredient name.

API Supply Chain3 active DMFs

3 active API suppliers hold Drug Master Files for this ingredient.

AIRGAS THERAPEUTICS LLCSULFUR HEXAFLUORIDE (SF6) GAS

DMF 150942000

FLUOROMED LPSULFUR HEXAFLUORIDE, 99.8%

DMF 373172023

SHANDONG APELOA TOSPO PHARMACEUTICAL CO LTDSULFUR HEXAFLUORIDE

DMF 429712025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 33.32%

0 patents0 exclusivities▴

POWDER;TOPICAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.